(Q30405929)

English

α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

avian influenza

1 reference

based on heuristic

inferred from title

4

object named as

Hongxuan He

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

3

object named as

Chengmin Wang

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Kai Li

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Jing Luo

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

10 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

7711-7717

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Are we ready for pandemic influenza?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Influenza virus-like particles containing M2 induce broadly cross protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Characterization of immunity induced by M2e of influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

A "universal" human influenza A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

NKT cells: what's in a name?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

CD1: antigen presentation and T cell function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Invariant NKT cells sustain specific B cell responses and memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

IFN-γ production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.136

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.07.136

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30405929&oldid=1966122228"